CASI Pharmaceuticals Inc (CASI)vsModerna Inc (MRNA)
CASI
CASI Pharmaceuticals Inc
$0.21
0.00%
HEALTHCARE · Cap: $4.26M
MRNA
Moderna Inc
$231.35
-6.97%
HEALTHCARE · Cap: $101.49B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 9305% more annual revenue ($2.52B vs $26.85M). MRNA leads profitability with a -110.5% profit margin vs -184.0%. MRNA earns a higher WallStSmart Score of 31/100 (F).
CASI
Avoid24
out of 100
Grade: F
MRNA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CASI.
Margin of Safety
+73.1%
Fair Value
$150.76
Current Price
$231.35
$80.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Large-cap with strong market position
Revenue surging 29.2% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1095.0% — below average capital efficiency
Trading at 13.7x book value
Weak financial health signals
ROE of -40.8% — below average capital efficiency
Earnings declined 85.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : CASI
The strongest argument for CASI centers on Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Revenue Growth. Revenue growth of 29.2% demonstrates continued momentum.
Bear Case : CASI
The primary concerns for CASI are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
CASI profiles as a turnaround stock while MRNA is a growth play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.17 — expect wider price swings.
MRNA is growing revenue faster at 29.2% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRNA scores higher overall (31/100 vs 24/100) and 29.2% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CASI Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · China
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and markets therapeutic and pharmaceutical products in China, the United States, and internationally. The company is headquartered in Rockville, Maryland.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?